U.S. FDA Approves Biogen’s SPINRAZA

U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy.The U.S. Food and Drug Administration (FDA) approved Biogen’s (NASDAQ: BIIB) SPINRAZA™ (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved in the U.S. for SMA, a leading genetic cause of death in infants and toddlers that is marked by progressive, debilitating muscle weakness.

URL:
www.businesswire.com/news/home/20161223005361/en/U.S.-FDA-Approves-Biogen%E2%80%99s-SPINRAZA%E2%84%A2-nusinersen-Treatment